



Original Article

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy



Sean M. O'Cathail^{a,*}, Thomas Smith^b, Rob Owens^c, Anthi Zeniou^d, Yatman Tsang^b, Daniel L.P. Holyoake^e, Louise Murray^d, Mark Harrison^b, Maria A. Hawkins^f

^a Institute of Cancer Sciences, University of Glasgow; ^b Mount Vernon Cancer Centre; ^c Oxford University NHS Foundation Trust; ^d Leeds Cancer Centre; ^e Norwich and Norfolk University NHS Foundation Trust; and ^f Medical Physics and Biomedical Engineering, University College London and University College London Hospitals NHS Foundation Trust, UK

ARTICLE INFO

Article history:

Received 12 May 2020

Received in revised form 14 August 2020

Accepted 19 August 2020

Available online 29 August 2020

Keywords:

Colorectal
Stereotactic
SBRT
Oligometastatic
Lymph node

ABSTRACT

Background: Stereotactic ablative radiotherapy (SBRT) is a radical option for oligometastatic colorectal cancer (CRC) patients, but most data relate to visceral metastases.

Methods: A prospective, multi-centre database of CRC patients treated with SBRT was interrogated. Inclusion criteria were ECOG PS 0–2, ≤ 3 sites of disease, a disease free interval of >6 months unless synchronous liver metastases. Primary endpoints were local control (LC), progression free survival (PFS) and overall survival (OS).

Results: 163 patients (172 metastases) were analysed. The median FU was 16 months (IQR 12.2–22.85). The LC at 1 year was 83.8% (CI 76.4%–91.9%) with a PFS of 55% (CI 47%–64.7%) respectively. LC at 1 year was 90% (CI 83%–99%) for nodal metastases (NM), 75% (63%–90%) for visceral metastases (VM). NM had improved median PFS (9 vs 19 months) [HR 0.6, CI 0.38–0.94, $p = 0.032$] and median OS (32 months vs not reached) [HR 0.28, CI 0.18–0.7, $p = 0.0062$] than VM, regardless of whether the NM were located inside or outside the pelvis. On multivariate analysis, NM and ECOG PS 0 were significant good prognostic factors. An exploratory analysis suggests KRAS WT is also a good prognostic factor.

Conclusion: Nodal site is an important prognostic determinant of SBRT that should be incorporated into patient selection. We hypothesise this may have an immunoeediting basis.

© 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 151 (2020) 280–286 This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Approximately 20% of colorectal cancer (CRC) patients present with stage IV disease [1]. Of those that present at an early stage and are treated radically, 20–30% will go on to develop metastatic disease [2,3]. Systemic therapy is the main treatment for metastases given the proven survival benefit, however metastasis directed therapy is increasingly being used to manage metastatic deposits in an attempt to achieve long term benefit [4]. Aggressive management of patients who have unresectable liver disease at the time of diagnosis [5] using radiofrequency ablation (RFA) has demonstrated an overall survival benefit versus standard of care [6]. The recent randomised phase II SABR-COMET trial demonstrated a survival benefit from the addition of stereotactic ablative body radiotherapy (SBRT) in oligometastatic disease at extracranial sites [7], where almost 20% of the patients had CRC. These data suggest that CRC patients can derive significant benefit in limited metastatic disease.

* Corresponding author at: Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, Garscube Campus, Switchback Road, Glasgow G61 1BD, UK.

E-mail address: Sean.O'Cathail@glasgow.ac.uk (S.M. O'Cathail).

The oligometastatic state lies on a spectrum between localised and disseminated disease [8]. A concrete definition is lacking with the most common criteria being the number and location of radiologically identifiable metastases. The ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, defines oligometastases as five or sometimes more metastases at two or three sites, primarily visceral and lymph nodes [9]. Data from surgical cohorts in CRC demonstrate an improved 5-year OS for patients with 1–3 resectable metastases, compared to 4–6, or more than 6, respectively [10], suggesting burden of disease is important. More recently there have been reports focusing on a specific primary cancer type or a specific treated metastatic site [11–15].

Visceral metastases (VM) are the most common metastases from CRC that are treated with SBRT [16] and much of the literature to date has focussed on either liver or lung metastases [17]. In the SABR-COMET trial [7] most patients had visceral metastases, while only 3 (6%) of metastases treated with SBRT were in lymph nodes. There are little data available on the outcomes of lymph node only oligometastases in colorectal cancer treated with SBRT.

The treatment options for these patients are limited to systemic therapy, as RFA and surgery are less commonly performed, and there is some debate about whether or not the entire nodal chain should be treated. Furthermore, the mechanisms of spread for visceral and nodal oligometastases differ which may have implication for outcomes.

We analysed a prospectively collected, multicentre cohort of oligometastatic CRC patients treated with SBRT to identify differences in outcomes between treated visceral metastases (VM) and lymph node metastases (NM) at oligometastatic sites.

Methods

Study population

Patients with CRC were identified from a prospectively collected register of patients [18] diagnosed with colorectal cancer treated across three UK sites (Oxford, Mount Vernon, Leeds). Key eligibility criteria were: confirmed histological diagnosis, ECOG PS 0–2, ≤ 3 sites of disease and no more than 2 organ systems, no brain metastases, primary tumour resected with a disease free interval of >6 months (synchronous presentations were permitted for liver metastases) as identified on multimodality imaging (CT, PET and MRI as appropriate), adequate organ function and no systemic treatment for 28 days or planned systemic treatment after SBRT. All nodes were confirmed as isolated through review of serial imaging. Patients with less than 3 months of follow were excluded. All metastatic lesions were treated, where there was more than one. All patients consented to collection of data as part of enrolment in the SBRT treatment program which had received ethical approval (North East – York Research Ethics Committee REC reference: 16_NE_0285).

Techniques of radiotherapy

All patients were scanned with helical CT using ≤ 5 mm interval. Gross tumour volume (GTV) was outlined and clinical target volume (CTV) was equal to GTV for all lesions except liver metastases where, a 5 mm margin in all directions was applied added to GTV to define CTV. Radiotherapy planning CT images were co-registered with diagnostic radiology at the treating oncologist’s discretion. Where disease sites were subject to internal movement (such as lung or liver), patients were planned using 4D-CT scan. Abdominal compression or fiducial tracking [19] was used for abdominal motion management. A margin of 3–5 mm, depending on disease site and dimensions, was added to GTV/ CTV to obtain the planning target volume (PTV). Details of radiation doses, which varied according to tumour sites, are provided in [Supplementary Table 1](#). An α/β ratio of 10 was used for biologically effective dose (BED) calculations. KRAS mutation status of the primary tumour was collected by retrospective review of pathology reports. All mutations were activating driver mutations and detected by next generation sequencing of the primary tumour using a targeted gene panel.

Response assessment

First evaluation was planned 3 months after the end of the SBRT and then every 3 months for the first year and every 6 months from the second to the fifth year. Follow-up visits included clinical evaluation and diagnostic imaging (CT, MRI or PET scan) at treating physician’s discretion. End points of the present study were local control (LC), defined as absence of progression inside the SBRT treated volume; locoregional progression (LRP), defined as progression outside the treated volume in an adjacent nodal station/

chain or within the same organ (liver/lung) and distant progression (DP), as metastasis within another organ system or anatomically remote from the treated lesion. Toxicity data was collected as part of the overall treatment program and is publically available [20].

Statistical analysis

All outcomes were calculated from date of SBRT treatment. Time to any progression (LC/LRP/DP) was defined as PFS and overall survival (OS) treatment to either death or censoring. Univariate analysis was performed with the log-rank test, and Cox proportional hazards regression was used to estimate hazard ratios (HR). The primary endpoints were PFS and OS. Multivariable stepwise cox regression analysis was performed to evaluate the association between clinical factors and survival, with a significance level of $p < 0.05$. Survival analysis was performed using Cox regression models and Kaplan Meier estimates with log rank testing. Median follow-up was ascertained by reverse-censoring method. Patients without the event of interest were censored at the time last known to be event-free. All statistical analysis was performed using R statistical software [21].

Results

A total of 184 patients were treated between September 2015 and October 2018. Nine were excluded as the treated site was intracranial and 12 excluded due to inadequate or missing follow up. The final cohort was 163 patients with 172 treated lesions. The median follow up was 16 months (IQR 12.2–22.85). The cohort characteristics are summarised in [Table 1](#). Toxicity was consistent

Table 1
Cohort characteristics.

| Variable | N = 163 | % |
|---|---|----|
| Age | 69 (Range 36–91) | |
| Gender | | |
| Male | 90 | 55 |
| Female | 73 | 45 |
| ECOG | | |
| 0 | 99 | 61 |
| 1 | 52 | 32 |
| 2 | 5 | 3 |
| Unknown | 7 | 4 |
| Primary site | | |
| Rectum | 81 | 50 |
| Colon | 82 | 50 |
| Treated site | | |
| Liver | 38 | 23 |
| Lymph Node | 86 | 53 |
| Lung | 34 | 21 |
| Other* | 5 | 3 |
| Median BED ₁₀ (across all sites) | 79.2 Gy (IQR 48–105) | |
| KRAS status | | |
| Wild type | 45 | 28 |
| Mutant | 19 | 12 |
| Not tested | 99 | 61 |
| GTV | 9.725 cm ³ (Range 2.03–39.2) | |
| Metachronous | 135 | 83 |
| Synchronous | 28 | 17 |
| Lines of chemotherapy | | |
| 0 | 38 | 23 |
| 1 | 86 | 53 |
| 2 | 34 | 21 |
| 3 | 2 | 1 |
| Number of metastases† | | |
| 1 | 151 | 93 |
| 2 | 10 | 6 |
| 3 | 2 | 1 |

*Tail of pancreas, left flank, pancreas bed, spine and penile bulb.

† >1 metastases treated as a single GTV are considered as isolated metastases.

with published series and is available elsewhere, with no deaths due to SBRT [20]. The median BED₁₀ for the all sites was 79.2 Gy. All lesions received the prescribed dose. Only 23% of patients had not received prior systemic therapy prior to SBRT. KRAS mutation status was available for 64 (39%) of patients.

The 1 and 2 year local control rate for the whole cohort was 83.8% (CI 76.4%–91.9%) and 77.4% (CI 67.9%–88.2%) respectively. However, the 1 year local control rate varied significantly different according to treated site; 58% for liver (36.7%–92.7%), 90% for lymph nodes (82.9%–99%) and 92% for lung (80.3%–100%).

In total, 86 patients with 95 lymph nodes metastases were treated. These were mapped to four anatomical locations: mediastinum, upper abdomen, para-aortic nodes and pelvic/inguinal nodes [Fig. 1]. 53 out of 95 (56%) of nodes never progressed. Of the remaining 42, only 2 progressed in-field and 12/42 (28%) progressed at multiple sites.

At 1 year and 2 years respectively, PFS for the whole cohort was 55% (CI 47%–64.7%) and 37.6% (CI 29%–48.8%) while OS was 93% (88.6%–98%) and 74% (CI 64.5%–85.4%). Median PFS for the whole cohort was 13.9 months, with median OS not reached. VM (liver, lung & bone) had a worse median PFS (9 months vs 19 months) and worse median OS (32 months vs not reached) than nodal metastatic sites, reflected in a statistically significant difference by Cox regression for PFS [HR 0.6, 95% 0.38–0.94, *p* = 0.032] and OS [HR 0.28, 95% 0.18–0.7, *p* = 0.0062] [Fig. 2]. On univariate analysis there was no significant in PFS difference for ECOG PS, primary site or synchronous/metachronous disease at presentation (Table 2). Patients in receipt of chemotherapy (adjuvant or metastatic) prior to SBRT had an increased hazard for progression [HR 1.93, C.I 1.08–3.45; *p* = 0.027]. On univariate analysis for OS, ECOG PS 1 or 2 were associated with an increased risk of death, relative to PS 0, but only the former was statistically significant with an overall low number (5) of PS 2 patients [Table 2]. Patients who had previously received systemic chemotherapy prior to SBRT had an increased hazard for progression [HR 1.93, CI 1.08–3.45; *p* = 0.027] and increased hazard for death, with a trend towards statistical significance.

Significant factors on univariate testing were included in a multivariate analysis for PFS and OS [Table 2], where VM remained significantly associated with poor outcomes. Inclusion of local control in a OS multivariate cox model showed that poor local control and an ECOG PS 1/2 were significantly associated with worse overall survival (Supplementary Table 2). NM site was associated with an improved OS outcome [HR 0.37, CI 0.14–0.95, *p* = 0.038].


To understand if the improved outcomes of NM was due to the large proportion of pelvic LN (50%), these were compared to distant, extra-pelvic NM sites and VM. On Cox regression analysis, relative to extra-pelvic LN, VM had an inferior PFS [HR 2.24, C.I 1.23–4.17; *p* = 0.008] and inferior OS [13.9, C.I 1.85–105.6; *p* = 0.01] but pelvic LN did not have significantly worse PFS [HR 1.86, C.I 0.94–3.68; *p* = 0.074] or OS [HR 8.15, C.I 0.97–67.85; *p* = 0.052] [Fig. 3].

The effect of KRAS mutation status was explored in the subgroup of patients for whom mutation testing of the primary tumour was available (*N* = 64), 30% of which were KRAS mutant. Other activating mutations, such as BRAF, were less common as expected [22], and not detected in sufficient numbers for analysis. There was no significant difference in the distribution of oligometastatic sites (liver, node, lung, bone) by KRAS mutation (Fisher's exact test, *p* = 0.346). There was no difference in local control rates between KRAS wild type and mutant cases (log rank *p* = 0.63) [Fig. 3A]. KRAS wild type was associated with improved PFS [HR 0.42, 95% CI 0.2–0.87; *p* = 0.02] and OS [HR 0.2, 95% CI 0.05–0.76; *p* = 0.02] [Supplementary Fig. 1]. The median PFS for wild type was 13 months versus 7 for mutant patients. On multivariate Cox regression analysis, nodal metastases and KRAS wild type remained significant prognostic factors [Nodal HR 0.09, 95% CI 0.02–0.4, *p* = 0.002; KRAS wild type HR 0.1, 95% 0.01–0.5, *p* = 0.007].

Discussion

In this prospectively collected, multicentre cohort study we showed patients having SBRT for nodal oligometastases enjoy better survival outcomes, relative to those treated for visceral metastases. The cohort was accrued over a short period of time (3 years) and had a LC at 1 and 2 years of 83.8% and 77.4%, respectively. LC in liver metastases appeared to be worse compared to other sites within the cohort and consistent with a systematic review of SBRT in CRC [23], which estimated wide variation local control rates for liver metastases of between 50%-100% at 1-year and 32%-91% at 2 years. Previous data had suggested that CRC patients with oligometastatic disease to liver have worse outcomes compared to other disease types treated with SBRT [13,24]. Radiosensitivity among liver metastases from CRC is heterogeneous compared to other sites [25] and this may account for the varying local controls rates [23].

A recent large single-centre CRC demonstrated 1-year local control of 95% and 3-year rate of >70% for the whole cohort [11].



| Site | DP | IFP | LRP | Multi | None | Total |
|-------------|----|-----|-----|-------|------|-------|
| Mediastinum | 2 | 0 | 3 | 0 | 6 | 11 |
| Abdomen | 1 | 0 | 1 | 2 | 14 | 18 |
| PA | 3 | 0 | 3 | 1 | 10 | 17 |
| Pelvis | 9 | 2 | 4 | 9 | 22 | 46 |
| Other | 1 | - | 1 | - | 1 | 3 |
| Total | 16 | 2 | 12 | 12 | 53 | 95 |

Fig. 1. Body diagram showing the anatomical sites of metastases with an associated count grid indicating the outcome (distant progression [DP], in field progression [IFP], locoregional progression [LRP]).




Fig. 2. Kaplan Meier plots with associated risk tables of progression free survival (A) and overall survival (B) outcomes for visceral (red) and nodal (blue) metastases.

Table 2
Univariate analysis for local control, progression free survival and overall survival.

| Variable | LC | | PFS | | OS | |
|---|-------------------|---------|------------------|---------|-------------------|---------|
| | HR (CI) | p value | HR (CI) | p value | HR (CI) | p value |
| ECOG PS | | | | | | |
| 0 | | | Reference | | | |
| 1 | 1.11 (0.43–2.86) | 0.831 | 1.02 (0.63–1.65) | 0.932 | 2.75 (1.13–6.68) | 0.025* |
| 2 | 2.28 (0.29–17.75) | 0.43 | 0.51 (0.07–3.71) | 0.506 | 4.85 (0.6–39.14) | 0.138 |
| Primary site | | | | | | |
| Rectum (ref Colon) | 0.88 (0.37–2.12) | 0.779 | 1.0 (0.64–1.55) | 0.984 | 0.7 (0.31–1.57) | 0.382 |
| Prior chemotherapy (ref no chemotherapy) | 1.71 (0.57–5.15) | 0.337 | 1.93 (1.08–3.45) | 0.027* | 3.18 (0.94–10.72) | 0.063 |
| Synchronous presentation (ref metachronous) | 0.88 (0.26–3.02) | 0.842 | 1.61 (0.96–2.71) | 0.070 | 1.32 (0.49–3.55) | 0.579 |
| Lymph node site (ref visceral site) | 0.6 (0.25–1.46) | 0.262 | 0.61 (0.39–0.96) | 0.032* | 0.29 (0.12–0.7) | 0.006* |

*Denotes statistically significant at the 0.05 level.

Although there was no difference in LC between lung vs non-lung metastases, they did not present the LC rates by site and had low numbers of nodal sites (12.4%). Factors which negatively influenced OS in multivariate analysis were non-lung sites [HR 1.97 (1.30–2.99), $p = 0.02$], CTV > 30 mm [HR 1.73 (1.18–2.55), $p = 0.03$], systemic therapy before SBRT [HR 1.61 (1.01–2.57), $p = 0.023$] and poor local control [HR 1.59 (1.04–2.43), $p = 0.007$]. Similar findings had been reported in a multi – tumour cohort

where prior systemic therapy resulted in worse LC [13]. A consistent interpretation is that achieving good local control of treated sites can lead to improved survival outcomes. Although local control, strictly speaking, is an outcome variable as opposed to pre-treatment variable, and thus has no use in selecting patients for SBRT, such analyses are common in SBRT cohorts. It should be noted however that assessment of local control could vary between reporting radiologists in a multi-institutional study,




Fig. 3. Kaplan Meier plots with associated risk tables of progression free survival (A) and overall survival (B) outcomes for pelvic NM, distant NM (outside the pelvis) and visceral metastases.

imaging modalities and anatomical sites, particularly liver lesions. Even though all participating centres were high volume, experienced, accredited SBRT institutions this is a potential weakness in our LC estimates.

The majority (56%) of nodal metastases never progressed in field during follow up. Of the 42 that did progress, 12 patients had LRP only and 28% had LRP and multi-site progression while 38% had distant disease. The pattern of relapse post SBRT justifies considering local tumoricidal treatments only to isolated nodal disease. Introduction of CTV around NM may decrease LRP but would increase toxicity. The excellent local control achieved with SBRT in nodal disease translated into an improved time to progression (19 vs 9 months) and sustained into an OS benefit. Conversely, worse local control as seen in the liver metastases, was associated with worse OS in the multivariate analysis [HR 3.3 (95% CI 1.35 – 8.78), $p = 0.016$]. Given that 50% of visceral metastases had progressed by 9 months suggests that in such patients SBRT and

systemic therapy could be better therapeutic approach, analogous to liver resections.

KRAS mutation has recently been shown to be a prognostic biomarker of worse survival outcomes in metastatic colorectal cancer in a large meta-analysis of first line randomised chemotherapy trials [26], an analogous situation to those referred for SBRT. Kinj et al found that KRAS mutation was associated with inferior metastasis free survival, but not OS, following SBRT in lung metastases [14]. In a randomised phase II trial of proton therapy for liver metastases KRAS mutants and TP53 mutants had worse local control than wild type patients [24]. A recent comprehensive study of tumour mutation status in a multisite cohort [27] demonstrated similar findings. Interestingly, although only 10% of their cohort, NM had 100% LC at 2 years. We suggest that KRAS mutation is a relevant prognostic factor in oligometastatic CRC and be incorporated as a stratifying factor into future SBRT studies.

Our study has limitations. Our median follow up is shorter than some published datasets [11,28,29], but not all [30], in part due to data collection permissions. However, the significant majority of relapse events after surgery occur in the first 2–3 years [2]. Our cohort had already accrued 6 months DFS prior to entry in the SBRT program, in addition to the median follow up which was calculated from date of SBRT. Our cohort represents a very clear subset of the recent ESTRO/EORTC OMD classifier [31] – metastatic oligorecurrence – which represents 83% [Table 1] and should be interpreted as such. We did not have histological and molecular mutation confirmation of every treated site and thus inferred KRAS status. KRAS status of the primary tumour shows high concordance with mutation status in tissue sampled from metastases [32–34] however. Given the small sample numbers of known KRAS patients, the analysis could be subject overfitting in MVA and is considered hypothesis generating.

Although a variety of radiotherapy doses were used, leading to range of BED, each site was treated consistently with the same dose. The schedules used are equivalent to those mandated in the SABR-COMET trial [7]. BED_{max} has previously been attributed to improved LC in liver metastases [12,13]. An analysis of dose effect on outcomes is not possible as it is confounded by treated site. Here, NM had the best LC despite the lowest prescription dose (BED₁₀ 60–93.3 Gy) suggesting more fundamental biological differences in radiation response between sites.

One potential working hypothesis for the observed differences are different routes of spread, with visceral metastases spreading haematologically and nodal metastases through the lymphatic system. The ability of the immune system to influence a cancer’s clinical course – “cancer immunoediting” – is marked by three distinct phases: elimination, equilibrium, and escape [35]. The clinical existence of oligometastases suggests that these tumours have escaped cancer immunoediting. LN are historically viewed as production sites for antigen-specific (adaptive) effector cells but they also contain a spatially co-ordinated diverse multicellular network of lymphoid cells (innate) that can rapidly generate a cytokine response [36]. Radiotherapy engages both the adaptive and innate immune system to convert the irradiated tumour into an ‘in-situ vaccine’ that elicits a tumour specific T-cell response [37]. In doing so, radiotherapy can assist recalibration of the immunoediting process, switching escape back to elimination and equilibrium. Once an oligometastatic site is treated, the ‘vaccinated’ individual may have the immune memory capacity to prevent (elimination) or defer (equilibrium) the development of synchronous disease sites.

In support of this theory, a recent study by Pitroda et al, of integrated molecular analysis of CRC metastases, an immune enriched subtype developed limited numbers of clinically evident synchronous metastases and was associated with improved survival outcomes [38]. These data would be consistent with the immunoediting hypothesis. Furthermore, they demonstrated that increased KRAS signalling was associated with worse survival outcomes, consistent with our data.

Treatment options for metastatic CRC are slow to progress compared to other common cancers, with cytotoxic chemotherapy still the mainstay of treatment. SBRT is an excellent tool that offers a radical, potentially curative, option to patients with limited disease spread. However, optimum selection of patients and sequencing of therapies to maximise benefit has yet to be clarified. The current study represents an important step forward in highlighting the need for biological selection of patients for SBRT, in addition to known clinical factors. A better understanding of the local and circulating immune response generated by SBRT is needed to fully explain the varying outcomes seen in this and other studies of oligometastatic CRC.

Conflict of interest

The authors have no relevant disclosures

Funding

SMO’C is a CRUK funded clinical senior lecturer at the Institute of Cancer Sciences (grant number CAN-RES-UK (C7932/A25142)). MAH is supported by funding from the NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust. LM is currently funded by Yorkshire Cancer Research (award number L389LM).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.radonc.2020.08.012>.

References

- [1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* 2015;65:87–108. <https://doi.org/10.3322/caac.21262>.
- [2] Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. *N Engl J Med* 2018;378:1177–88. <https://doi.org/10.1056/NEJMoa1713709>.
- [3] Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2015;16:979–89. [https://doi.org/10.1016/S1470-2045\(15\)00159-X](https://doi.org/10.1016/S1470-2045(15)00159-X).
- [4] Chua TC, Liauw W, Chu F, Morris DL. Viewing Metastatic Colorectal Cancer as a Curable Chronic Disease. *Am J Clin Oncol* 2012;35:77. <https://doi.org/10.1097/COC.0b013e3181fe4444>.
- [5] Taylor I. Liver metastases from colorectal cancer: Lessons from past and present clinical studies. *BJS Br J Surg* 1996;83:456–60. <https://doi.org/10.1002/bjs.1800830406>.
- [6] Ruers T, Van Coevorden F, Punt CJA, Pierie J-P-E-N, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II Trial. *JNCI J Natl Cancer Inst* 2017;109. <https://doi.org/10.1093/jnci/djx015>.
- [7] Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. *Lancet* 2019;393:2051–8. [https://doi.org/10.1016/S0140-6736\(18\)32487-5](https://doi.org/10.1016/S0140-6736(18)32487-5).
- [8] Weichselbaum RR, Hellman S. Oligometastases revisited. *Nat Rev Clin Oncol* 2011;8:378–82. <https://doi.org/10.1038/nrclinonc.2011.44>.
- [9] Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016;27:1386–422. <https://doi.org/10.1093/annonc/mdw235>.
- [10] Elias D, Liberale G, Vernerey D, Pocard M, Ducreux M, Boige V, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. *Ann Surg Oncol* 2005;12:900–9. <https://doi.org/10.1245/ASO.2005.01.010>.
- [11] Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, et al. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. *Radiother Oncol* 2019;133:220–6. <https://doi.org/10.1016/j.radonc.2018.10.024>.
- [12] Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, et al. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. *BMC Cancer* 2018;18:283. <https://doi.org/10.1186/s12885-018-4191-2>.
- [13] Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease – Influence of pre-treatment chemotherapy and histology on local tumor control. *Radiother Oncol* 2017;123:227–33. <https://doi.org/10.1016/j.radonc.2017.01.013>.
- [14] Kinj R, Bondiau P-Y, François E, Gérard J-P, Naghavi AO, Leysalle A, et al. Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy. *Clin Colorectal Cancer* 2017;16:e211–20. <https://doi.org/10.1016/j.clcc.2016.08.003>.
- [15] Wang X, Zamdberg L, Ye H, Grills IS, Yan D. A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from

- colorectal cancer versus early stage non-small cell lung cancer. *BMC Cancer* 2018;18:962. <https://doi.org/10.1186/s12885-018-4865-9>.
- [16] Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, Alfonso PG, et al. Treatment recommendations for metastatic colorectal cancer. *Clin Transl Oncol* 2011;13:162–78. <https://doi.org/10.1007/s12094-011-0636-7>.
- [17] Berkovic P, Gulyban A, Defraene G, Swenen L, Dechambre D, Nguyen PV, et al. Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases. *BMC Cancer* 2020;20:402. <https://doi.org/10.1186/s12885-020-06906-1>.
- [18] SABR CTe v2.0. Health Res Auth n.d. /planning-and-improving-research/application-summaries/research-summaries/sabr-cte-v20/ (accessed May 8, 2020).
- [19] Choi J-H, Seo D-W, Park DH, Lee SK, Kim M-H. Fiducial placement for stereotactic body radiation therapy under only endoscopic ultrasonography guidance in pancreatic and hepatic malignancy: practical feasibility and safety. *Gut Liver* 2014;8:88–93. <https://doi.org/10.5009/gnl.2014.8.1.88>.
- [20] Stereotactic Ablative Radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages) - NHS England - Citizen Space n.d. <https://www.engage.england.nhs.uk/consultation/sabr-metachronous-extracranial-oligometastatic/> (accessed May 8, 2020).
- [21] Core R, Team R. *A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2016.
- [22] Network TCGA. Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 2012;487:330–7. <https://doi.org/10.1038/nature11252>.
- [23] Kobiela J, Spychalski P, Marvaso G, Ciardo D, Dell'Acqua V, Kraja F, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review. *Crit Rev Oncol Hematol* 2018;129:91–101. <https://doi.org/10.1016/j.critrevonc.2018.06.005>.
- [24] Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H, et al. Phase II study of proton-based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. *JNCI J Natl Cancer Inst* 2017;109. <https://doi.org/10.1093/jnci/djx031>.
- [25] Ahmed KA, Caudell JJ, El-Haddad G, Berglund AE, Welsh EA, Yue B, et al. Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. *Int J Radiat Oncol* 2016;95:1399–404. <https://doi.org/10.1016/j.ijrobp.2016.03.050>.
- [26] Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, et al. Personalizing survival predictions in advanced colorectal cancer: The ARCAD nomogram project. *JNCI J Natl Cancer Inst* 2018;110:638–48. <https://doi.org/10.1093/jnci/djx253>.
- [27] Jethwa KR, Jang S, Mullikin TC, Harmsen WS, Petersen MM, Olivier KR, et al. Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. *Radiother Oncol* 2020;146:29–36. <https://doi.org/10.1016/j.radonc.2020.02.008>.
- [28] Scorsetti M, Comito T, Clerici E, Franzese C, Tozzi A, Iftode C, et al. Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. *Radiat Oncol Lond Engl* 2018;13. <https://doi.org/10.1186/s13014-018-1185-9>.
- [29] Thompson R, Cheung P, Chu W, Myrehaug S, Poon I, Sahgal A, et al. Outcomes of extra-cranial stereotactic body radiotherapy for metastatic colorectal cancer: Dose and site of metastases matter. *Radiother Oncol* 2020;142:236–45. <https://doi.org/10.1016/j.radonc.2019.08.018>.
- [30] Dell'Acqua V, Surgo A, Kraja F, Kobiela J, Zerella MA, Spychalski P, et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. *Clin Exp Metastasis* 2019;36:331–42. <https://doi.org/10.1007/s10585-019-09976-z>.
- [31] Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. *Lancet Oncol* 2020;21:e18–28. [https://doi.org/10.1016/S1470-2045\(19\)30718-1](https://doi.org/10.1016/S1470-2045(19)30718-1).
- [32] Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. *Ann Surg Oncol* 2010;17:1429–34. <https://doi.org/10.1245/s10434-009-0864-z>.
- [33] Knijn N, Mekenkamp LJM, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. *Br J Cancer* 2011;104:1020–6. <https://doi.org/10.1038/bjc.2011.26>.
- [34] Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. *Oncologist* 2008;13:1270–5. <https://doi.org/10.1634/theoncologist.2008-0181>.
- [35] Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* 2007;450:903–7. <https://doi.org/10.1038/nature06309>.
- [36] Kastenmüller W, Torabi-Parizi P, Subramanian N, Lämmermann T, Germain RN. A spatially-organized multicellular innate immune response in lymph nodes limits systemic pathogen spread. *Cell* 2012;150:1235–48. <https://doi.org/10.1016/j.cell.2012.07.021>.
- [37] Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. *JNCI J Natl Cancer Inst* 2013;105:256–65. <https://doi.org/10.1093/jnci/djs629>.
- [38] Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. *Nat Commun* 2018;9:1793. <https://doi.org/10.1038/s41467-018-04278-6>.